{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:40:42Z","timestamp":1786984842166,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.atherosclerosis.2007.07.004","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T07:23:07Z","timestamp":1188976987000},"page":"710-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey"],"prefix":"10.1016","volume":"197","author":[{"given":"K.","family":"Kotseva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stagmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Bacquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 people with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older people with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in people with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Cur Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib6","first-page":"494","article-title":"Intensive versus moderate lipid-lowering with statins after acute coronary syndromes (PROVE-IT)","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib8","first-page":"1","article-title":"Intensive lipid-lowering with atorvastatin in patients with stable coronary disease","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High dose atorvastatin vs. usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/hrt.2003.027284","article-title":"Beneficial effects of fluvastatin following percutaneous coronary intervention in people with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)","volume":"90","author":"Lee","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs. a delayed conservative simvastatin strategy in people with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol increasing compounds. A meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib16","first-page":"1300","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension","volume":"15","author":"Py\u00f6r\u00e4l\u00e4","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/oxfordjournals.eurheartj.a015136","article-title":"A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results","volume":"18","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib18","first-page":"505","article-title":"Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study","volume":"153","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention","volume":"19","author":"Wood","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme","volume":"22","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(00)04235-5","article-title":"Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of low density lipoprotein cholesterol concentration without the use of preparative ultracentrofuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199701163360301","article-title":"The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/euhj.2001.2775","article-title":"Effects of pravastatin on mortality in people with and without coronary heart disease across a broad range of cholesterol levels. The prospective pravastatin pooling project","volume":"23","author":"Simes","year":"2002","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.atherosclerosis.2007.07.004_bib26","first-page":"S1","volume":"10","author":"De Backer","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib27","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106:3143\u20133221.","DOI":"10.1161\/circ.106.25.3143"},{"key":"10.1016\/j.atherosclerosis.2007.07.004_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"NCEP Report: implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines","volume":"110","year":"2004","journal-title":"Circulation"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007004480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915007004480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:32:30Z","timestamp":1758155550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915007004480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0021915007004480"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.07.004","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}